pirenzepine has been researched along with Behavior Disorders in 27 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of olanzapine for the treatment of psychotic and behavioral disturbances in Alzheimer disease." | 8.82 | Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. ( Schatz, RA, 2003) |
| "To evaluate weight gain associated with olanzapine, risperidone, and haloperidol treatment and its clinical risk factors in adolescent patients." | 7.71 | Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. ( Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R, 2002) |
| "Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization." | 7.70 | Body weight and leptin plasma levels during treatment with antipsychotic drugs. ( Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 1999) |
| "Olanzapine is an atypical antipsychotic that is becoming more widely used in children and adolescents." | 5.31 | Hyperglycemia and hypertriglyceridemia secondary to olanzapine. ( Domon, SE; Webber, JC, 2001) |
| "To evaluate the efficacy and safety of olanzapine for the treatment of psychotic and behavioral disturbances in Alzheimer disease." | 4.82 | Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. ( Schatz, RA, 2003) |
| "The most convincing evidence of the efficacy of atypical neuroleptics in children and adolescents concerns clozapine in the treatment of schizophrenia." | 4.80 | Use of atypical neuroleptics in child and adolescent psychiatry. ( Laor, N; Toren, P; Weizman, A, 1998) |
| " This article will describe the potential use of the atypical antipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depression and mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders, dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patients with mental retardation or developmental delays." | 4.79 | Olanzapine and the new generation of antipsychotic agents: patterns of use. ( Glazer, WM, 1997) |
| "To evaluate weight gain associated with olanzapine, risperidone, and haloperidol treatment and its clinical risk factors in adolescent patients." | 3.71 | Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. ( Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R, 2002) |
| "Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization." | 3.70 | Body weight and leptin plasma levels during treatment with antipsychotic drugs. ( Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 1999) |
| " A numerical decrease in the dosage of concurrent conventional antipsychotic medications occurred over the course of the first 6 months of olanzapine therapy, and a statistically significant (p <." | 2.71 | Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. ( Barnhill, LJ; Davis, JM; Janowsky, DS, 2003) |
| "Olanzapine is a recently introduced atypical neuroleptic agent for which little information is available on its use in children." | 2.69 | Open-label olanzapine treatment in five preadolescent children. ( King, BH; Krishnamoorthy, J, 1998) |
| " This is because of their efficacy in the treatment of several psychiatric disorders, ease of administration, and absence of the well-known extrapyramidal adverse effects long-attributed to the standard dopamine blocking anti-psychotic medications." | 2.42 | Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician. ( Bailey, RK, 2003) |
| "Available toxicity data concerning olanzapine were obtained from the Offices of the Medical Examiners of Canada, the Canadian Adverse Drug Reaction Monitoring Program and a review of the literature." | 2.42 | A review of olanzapine-associated toxicity and fatality in overdose. ( Chue, P; Singer, P, 2003) |
| "Olanzapine is an atypical antipsychotic that is becoming more widely used in children and adolescents." | 1.31 | Hyperglycemia and hypertriglyceridemia secondary to olanzapine. ( Domon, SE; Webber, JC, 2001) |
| "A 45-year-old man with well-controlled type 2 diabetes mellitus experienced an abrupt worsening of his diabetes after 3 years of olanzapine therapy His hemoglobin A1c (HbA1c) level rose from a baseline of 5." | 1.31 | Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. ( Bechara, CI; Goldman-Levine, JD, 2001) |
| "Olanzapine-treated subjects used less as needed (PRN) antipsychotic medication compared to pre-olanzapine treatment period." | 1.31 | The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital. ( Atzert, R; Baird, JW; Brar, JS; Chakravorty, S; Chalasani, L; Chengappa, KN; Delaney, JA; Levine, J; Parepally, H; Patel, AM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (29.63) | 18.2507 |
| 2000's | 19 (70.37) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gex-Fabry, M | 1 |
| Balant-Gorgia, AE | 1 |
| Balant, LP | 1 |
| Bailey, RK | 2 |
| Edell, WS | 2 |
| Rupnow, MF | 1 |
| Motsinger, CD | 1 |
| Perron, GA | 1 |
| Lacy, TJ | 1 |
| Chue, P | 1 |
| Singer, P | 1 |
| Schatz, RA | 1 |
| Reeves, RR | 1 |
| Torres, RA | 1 |
| Ushizima, M | 2 |
| Amano, N | 1 |
| Janowsky, DS | 1 |
| Barnhill, LJ | 1 |
| Davis, JM | 1 |
| Marzuk, PM | 1 |
| Barchas, JD | 1 |
| Glazer, WM | 1 |
| Strauss, AJ | 1 |
| Dralle, PW | 1 |
| Eschmann, AJ | 1 |
| Wagner, RB | 1 |
| Krishnamoorthy, J | 1 |
| King, BH | 1 |
| Toren, P | 1 |
| Laor, N | 1 |
| Weizman, A | 1 |
| Kraus, T | 1 |
| Haack, M | 1 |
| Schuld, A | 1 |
| Hinze-Selch, D | 1 |
| Kühn, M | 1 |
| Uhr, M | 1 |
| Pollmächer, T | 1 |
| Buckley, PF | 1 |
| Margolese, HC | 1 |
| Chouinard, G | 1 |
| Nyfort-Hansen, K | 1 |
| Alderman, CP | 1 |
| Wetterling, T | 1 |
| Noordsy, DL | 1 |
| O'Keefe, C | 1 |
| Mueser, KT | 1 |
| Xie, H | 1 |
| Tunis, SL | 1 |
| Domon, SE | 1 |
| Webber, JC | 1 |
| Bechara, CI | 1 |
| Goldman-Levine, JD | 1 |
| Cohn, TA | 1 |
| Remington, G | 1 |
| Kameh, H | 1 |
| Ratzoni, G | 1 |
| Gothelf, D | 1 |
| Brand-Gothelf, A | 1 |
| Reidman, J | 1 |
| Kikinzon, L | 1 |
| Gal, G | 1 |
| Phillip, M | 1 |
| Apter, A | 1 |
| Weizman, R | 1 |
| Parepally, H | 1 |
| Chakravorty, S | 1 |
| Levine, J | 1 |
| Brar, JS | 1 |
| Patel, AM | 1 |
| Baird, JW | 1 |
| Chalasani, L | 1 |
| Delaney, JA | 1 |
| Atzert, R | 1 |
| Chengappa, KN | 1 |
| Burges Watson, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
8 reviews available for pirenzepine and Behavior Disorders
| Article | Year |
|---|---|
Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.
Topics: Adult; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Black or African American; | 2003 |
A review of olanzapine-associated toxicity and fatality in overdose.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Overdose; Humans; Mental Disorders; Olanzapine; Pirenzep | 2003 |
Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Humans; Mental Disorders; Olanzapine; Pire | 2003 |
[Brain tumor].
Topics: Antipsychotic Agents; Benzodiazepines; Brain Neoplasms; Haloperidol; Humans; Hydrocephalus; Immunogl | 2003 |
Olanzapine and the new generation of antipsychotic agents: patterns of use.
Topics: Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Dementia; Depressive Disorder; Developmen | 1997 |
Use of atypical neuroleptics in child and adolescent psychiatry.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Child; Child Development Diso | 1998 |
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol | 1999 |
Bodyweight gain with atypical antipsychotics. A comparative review.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Mental Disorders; Olan | 2001 |
3 trials available for pirenzepine and Behavior Disorders
| Article | Year |
|---|---|
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disor | 2003 |
Open-label olanzapine treatment in five preadolescent children.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzod | 1998 |
Six-month outcomes for patients who switched to olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Chlorpromazine; Dose-R | 2001 |
16 other studies available for pirenzepine and Behavior Disorders
| Article | Year |
|---|---|
Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication.
Topics: Age Factors; Benzodiazepines; Confidence Intervals; Dose-Response Relationship, Drug; Drug Interacti | 2003 |
Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cost Savings; Dib | 2003 |
Use of atypical antipsychotic drugs in patients with dementia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; Dementia; Dibenzothiazepines; H | 2003 |
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepi | 2003 |
Psychiatry.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Learning; Mental Disorders; Neuroanatomy; Olanzapine; | 1997 |
Conventional psychotropic-induced tremor extinguished by olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Fluphenazine; Haloperidol; Humans; Male; Menta | 1998 |
Body weight and leptin plasma levels during treatment with antipsychotic drugs.
Topics: Adipose Tissue; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 1999 |
Olanzapine-induced neuroleptic malignant syndrome with mental retardation.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Humans; Intellectual Disability; Male; Me | 1999 |
Possible neuroleptic malignant syndrome associated with olanzapine.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Fever; Humans; Male; Mental Disorder | 2000 |
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Depre | 2001 |
Hyperglycemia and hypertriglyceridemia secondary to olanzapine.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Humans; Hyperglycemia; Hypertriglyceridemia; Male | 2001 |
Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy.
Topics: Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hyperglycemi | 2001 |
Hyperinsulinemia in psychiatric patients treated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Fasting; Female; Humans; Hyperinsulinis | 2002 |
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Mental Disorde | 2002 |
The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Chi-Square | 2002 |
Uses of olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Mental Disorders; Olanzapine; Pirenzepine | 2002 |